---
title: Certara vs Medpace
slug_a: certara
slug_b: medpace
site: cro
review_signal_gate: closed
canonical_path: /compare/certara/medpace
generated_by: BioBM Editorial AI
---

# Certara vs Medpace

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Certara (certara) is listed for cro. Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.

Services: 37. Modalities: 20. Indications: 25. Locations: 8. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (37).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

Medpace (medpace) is listed for cro. Full-service CRO with 30+ years of organic growth, offering integrated clinical development services across all phases with wholly-owned central labs, bioanalytical lab, imaging core lab, and Phase I unit.

Services: 34. Modalities: 7. Indications: 13. Locations: 22. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (34).

Review summary: Review summary withheld until site-level review gate opens.